sub:assertion {
  d:DB06594 v:identifier "DB06594" ;
    v:namespace "drugbank" ;
    v:uri "http://bio2rdf.org/drugbank:DB06594" ;
    v:x-identifiers.org <http://identifiers.org/drugbank/DB06594> ;
    dv:drugbank-id "DB06594" ;
    dv:x-atc <http://bio2rdf.org/atc:N06AX22> ;
    dv:x-bindingdb <http://bio2rdf.org/bindingdb:50035179> ;
    dv:x-cas <http://bio2rdf.org/cas:138112-76-2> ;
    dv:x-chemspider <http://bio2rdf.org/chemspider:74141> ;
    dv:x-kegg <http://bio2rdf.org/kegg:D02578> ;
    dv:x-pharmgkb <http://bio2rdf.org/pharmgkb:PA165958363> ;
    dv:x-pubchemcompound <http://bio2rdf.org/pubchem.compound:82148> ;
    dv:x-wikipedia <http://bio2rdf.org/wikipedia:Agomelatine> ;
    dct:description """Agomelatine is structurally closely related to melatonin. Agomelatine is a potent agonist at melatonin receptors and an antagonist at serotonin-2C (5-HT2C) receptors, tested in an animal model of depression. Agomelatine was discovered and developed by the European pharmaceutical company Servier Laboratories Ltd. Servier continue to develop the drug and conduct phase III trials in the European Union. In 2005 Servier submitted Agomelatine to the European Medicines Agency (EMEA). On 27 July 2006 the Committee for Medical Products for Human Use (CHMP) of the EMEA recommended a refusal of the marketing authorisation of Valdoxan/Thymanax. The major concern was that efficacy had not been sufficiently shown. In 2006 Servier sold the rights to develop Agomelatine in the US to Novartis.

The development for the US market was discontinued in October 2011. It is currently sold in Australia under the Valdoxan trade name."""@en ;
    dct:identifier "drugbank:DB06594" ;
    dct:title "Agomelatine"@en ;
    a dv:Drug ;
    rdfs:label "Agomelatine [drugbank:DB06594]"@en ;
    rdfs:seeAlso <http://www.drugbank.ca/drugs/DB06594> .
}